Resveratrol activates the histone H2B ubiquitin ligase, RNF20, in MDA-MB-231 breast cancer cells

Journal of Functional Foods

Volumn 5, Issue 2, 2013, Pages 790-800

  Lin, Chia Yeh ^a,b   Hsiao, Wei Chun ^b   Wright, Duncan Edward ^b   Hsu, Chia Ling ^b   Lo, Yi Chen ^c   Wang Hsu, Guoo Shyng ^a   Kao, Cheng Fu ^b  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Cell growth; H2B ubiquitylation; P21; Resveratrol; RNF20

Indexed keywords

VITACEAE;

EID: 84876740961     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2013.01.025     Document Type: Article

References (60)

1. Abbas T., Dutta A. p21 in cancer: Intricate networks and multiple activities. Nature Reviews Cancer 2009, 9(6):400-414.
2. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Research 2004, 24(5A):2783-2840.
3. Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Research 2006, 8(4):R38.
4. Bishayee A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prevention Research (Phila) 2009, 2(5):409-418.
5. Bourguignon L.Y., Xia W., Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. The Journal of Biological Chemistry 2009, 284(5):2657-2671.
6. Briggs S.D., Xiao T., Sun Z.W., Caldwell J.A., Shabanowitz J., Hunt D.F., Allis C.D., Strahl B.D. Gene silencing: Trans-histone regulatory pathway in chromatin. Nature 2002, 418(6897):498.
7. Buro L.J., Chipumuro E., Henriksen M.A. Menin and RNF20 recruitment is associated with dynamic histone modifications that regulate signal transducer and activator of transcription 1 (STAT1)-activated transcription of the interferon regulatory factor 1 gene (IRF1). Epigenetics & Chromatin 2010, 3(1):16.
8. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry 2009, 55(4):611-622.
9. Cebrian A., Pharoah P.D., Ahmed S., Ropero S., Fraga M.F., Smith P.L., Conroy D., Luben R., Perkins B., Easton D.F., Dunning A.M., Esteller M., Ponder B.A. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006, 27(8):1661-1669.
10. Chang C.Y., Lee T.H., Sheu W.H.-H. Anti-atherogenic effects of resveratrol via liver X receptor α-dependent upregulation of ATP-binding cassette transporters A1 and G1 in macrophages. Journal of Functional Foods 2012, 4(4):727-735.
11. Chung E.Y., Kim B.H., Hong J.T., Lee C.K., Ahn B., Nam S.Y., Han S.B., Kim Y. Resveratrol down-regulates interferon-gamma-inducible inflammatory genes in macrophages: Molecular mechanism via decreased STAT-1 activation. The Journal of Nutritional Biochemistry 2010, 22(10):902-909.
12. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4):817-825.
13. Espinosa J.M. Histone H2B ubiquitination: The cancer connection. Genes & Development 2008, 22(20):2743-2749.
14. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics 2007, 8(4):286-298.
15. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. The New England Journal of Medicine 2010, 363(20):1938-1948.
16. Gao Z., Xu M.S., Barnett T.L., Xu C.W. Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells. Biochemical and Biophysical Research Communications 2011, 407(2):271-276.
17. Gehm B.D., McAndrews J.M., Chien P.Y., Jameson J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(25):14138-14143.
18. Harikumar K.B., Aggarwal B.B. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7(8):1020-1035.
19. Hoshino I., Matsubara H. Recent advances in histone deacetylase targeted cancer therapy. Surgery Today 2010, 40(9):809-815.
20. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954):191-196.
21. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA - A Cancer Journal for Clinicians 2011, 61(2):69-90.
22. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293(5532):1074-1080.
23. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
24. Jones P.A., Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001, 293(5532):1068-1070.
25. Jovanovic J., Ronneberg J.A., Tost J., Kristensen V. The epigenetics of breast cancer. Molecular Oncology 2010, 4(3):242-254.
26. Kao C.F., Hillyer C., Tsukuda T., Henry K., Berger S., Osley M.A. Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B. Genes & Development 2004, 18(2):184-195.
27. Katayose D., Gudas J., Nguyen H., Srivastava S., Cowan K.H., Seth P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clinical Cancer Research 1995, 1(8):889-897.
28. Kim J., Hake S.B., Roeder R.G. The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Molecular Cell 2005, 20(5):759-770.
29. Kundu J.K., Surh Y.J. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutation Research 2004, 555(1-2):65-80.
30. Kundu J.K., Surh Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Letters 2008, 269(2):243-261.
31. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127(6):1109-1122.
32. Le Corre L., Chalabi N., Delort L., Bignon Y.J., Bernard-Gallon D.J. Resveratrol and breast cancer chemoprevention: Molecular mechanisms. Molecular Nutrition & Food Research 2005, 49(5):462-471.
33. Lee M.F., Pan M.H., Chiou Y.S., Cheng A.C., Huang H. Resveratrol modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells. Journal of Agricultural and Food Chemistry 2011, 59(21):11853-11861.
34. Lin J.N., Lin V.C., Rau K.M., Shieh P.C., Kuo D.H., Shieh J.C., Chen W.J., Tsai S.C., Way T.D. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. Journal of Agricultural and Food Chemistry 2009, 58(3):1584-1592.
35. Liu P.L., Tsai J.R., Charles A.L., Hwang J.J., Chou S.H., Ping Y.H., Lin F.Y., Chen Y.L., Hung C.Y., Chen W.C., Chen Y.H., Chong I.W. Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Molecular Nutrition & Food Research 2010, 54(Suppl. 2):S196-S204.
36. Lo P.K., Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 2008, 9(12):1879-1902.
37. Lu R., Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. Journal of Cellular Physiology 1999, 179(3):297-304.
38. Mai A., Altucci L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. The International Journal of Biochemistry & Cell Biology 2009, 41(1):199-213.
39. Mao Q.Q., Bai Y., Lin Y.W., Zheng X.Y., Qin J., Yang K., Xie L.P. Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Molecular Nutrition & Food Research 2010, 54(11):1574-1584.
40. Michel E., Parsons J.A. Characterization of a biotin-conjugated ovine prolactin ligand. Molecular and Cellular Endocrinology 1988, 56(1-2):71-79.
41. Murray A.W. Recycling the cell cycle: Cyclins revisited. Cell 2004, 116(2):221-234.
42. Neven P., Pochet N., Drijkoningen M., Amant F., De Smet F., Paridaens R., Christiaens M.R., Vergote I. Progesterone receptor in estrogen receptor-positive breast cancer: The association between HER-2 and lymph node involvement is age related. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2006, 24(16):2595. author reply 2595-2597.
43. Ogryzko V.V., Wong P., Howard B.H. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Molecular and Cellular Biology 1997, 17(8):4877-4882.
44. Paluszczak J., Krajka-Kuzniak V., Baer-Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicology Letters 2010, 192(2):119-125.
45. Papoutsis A.J., Lamore S.D., Wondrak G.T., Selmin O.I., Romagnolo D.F. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. Journal of Nutrition 2010, 140(9):1607-1614.
46. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA - A Cancer Journal for Clinicians 2005, 55(2):74-108.
47. Pennock S., Wang Z. A tale of two Cbls: Interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Molecular and Cellular Biology 2008, 28(9):3020-3037.
48. Pozo-Guisado E., Alvarez-Barrientos A., Mulero-Navarro S., Santiago-Josefat B., Fernandez-Salguero P.M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: Cell-specific alteration of the cell cycle. Biochemical Pharmacology 2002, 64(9):1375-1386.
49. Reid G., Gallais R., Metivier R. Marking time: The dynamic role of chromatin and covalent modification in transcription. The International Journal of Biochemistry & Cell Biology 2009, 41(1):155-163.
50. Ross S.A., Dwyer J., Umar A., Kagan J., Verma M., Van Bemmel D.M., Dunn B.K. Introduction: Diet, epigenetic events and cancer prevention. Nutrition Reviews 2008, 66(Suppl. 1):S1-S6.
51. Shema E., Kim J., Roeder R.G., Oren M. RNF20 inhibits TFIIS-facilitated transcriptional elongation to suppress pro-oncogenic gene expression. Molecular Cell 2011, 42(4):477-488.
52. Shema E., Tirosh I., Aylon Y., Huang J., Ye C., Moskovits N., Raver-Shapira N., Minsky N., Pirngruber J., Tarcic G., Hublarova P., Moyal L., Gana-Weisz M., Shiloh Y., Yarden Y., Johnsen S.A., Vojtesek B., Berger S.L., Oren M. The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes & Development 2008, 22(19):2664-2676.
53. Silva J., Silva J.M., Dominguez G., Garcia J.M., Cantos B., Rodriguez R., Larrondo F.J., Provencio M., Espana P., Bonilla F. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. The Journal of Pathology 2003, 199(3):289-297.
54. Sun Z.W., Allis C.D. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 2002, 418(6893):104-108.
55. Vanamala J., Reddivari L., Radhakrishnan S., Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010, 1:238.
56. Veeck J., Esteller M. Breast cancer epigenetics: From DNA methylation to microRNAs. Journal of Mammary Gland Biology and Neoplasia 2010, 15(1):5-17.
57. Wang R.H., Zheng Y., Kim H.S., Xu X., Cao L., Luhasen T., Lee M.H., Xiao C., Vassilopoulos A., Chen W., Gardner K., Man Y.G., Hung M.C., Finkel T., Deng C.X. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Molecular Cell 2008, 32(1):11-20.
58. Youlden D.R., Cramb S.M., Dunn N.A., Muller J.M., Pyke C.M., Baade P.D. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiology 2012, 36(3):237-248.
59. Zhang Y. Transcriptional regulation by histone ubiquitination and deubiquitination. Genes & Development 2003, 17(22):2733-2740.
60. Zhu B., Zheng Y., Pham A.D., Mandal S.S., Erdjument-Bromage H., Tempst P., Reinberg D. Monoubiquitination of human histone H2B: The factors involved and their roles in HOX gene regulation. Molecular Cell 2005, 20(4):601-611.